Cancers, Free Full-Text

Imatinib became the standard treatment for chronic myeloid leukemia (CML) about 20 years ago, which was a major breakthrough in stabilizing the pathology and improving the quality of life of patients. However, the emergence of resistance to imatinib and other tyrosine kinase inhibitors leads researchers to characterize new therapeutic targets. Several studies have highlighted the role of histone deacetylase 6 (HDAC6) in various pathologies, including cancer. This protein effectively intervenes in cellular activities by its primarily cytoplasmic localization. In this review, we will discuss the molecular characteristics of the HDAC6 protein, as well as its overexpression in CML leukemic stem cells, which make it a promising therapeutic target for the treatment of CML.

Cancers, Free Full-Text

Thoracic Cancer - Wiley Online Library

I Am Cancer Free! - Cancer Free Gift - Pin

CA: A Cancer Journal for Clinicians - Wiley Online Library

Free PSD Breast cancer awareness editable text effect

Harboring Hard and Soft Cells Lets Tumors Grow and Metastasize Simultaneously

Pathology Outlines - Carcinoma-general

Artificial intelligence-aided clinical annotation of a large multi-cancer genomic dataset

Pancreatic Cancer Action Network – Research, Patient Support, Resources

Know the signs of cancer to catch it early

Rare Cancer Day - National Organization for Rare Disorders

Emerging Utility of Urinary Cell-free Nucleic Acid Biomarkers for Prostate, Bladder, and Renal Cancers - European Urology Focus

Cancers, Free Full-Text